As a corporately driven organization, the MedTech Board of Directors is comprised of senior officers of manufacturing companies.
Executive VP & Chief Marketing Officer, Welch Allyn
Scott Gucciardi leads the global marketing function for Welch Allyn, bringing together a customer-focused organization to drive the company’s solutions strategy. Scott began his career at Welch Allyn in 1990 as a manufacturing systems project engineer and soon after moved into the new product development function as a quality engineer. He then held management positions of increasing responsibility in product management, marketing, and strategic business unit management, with a focus on innovation in ophthalmic diagnostic devices. Scott most recently served as an executive vice president and chief new product development officer responsible for leading Welch Allyn’s research and development.
Scott has a bachelor’s degree in mechanical engineering from Clarkson University and a MBA from the University of Rochester’s Simon School.
VP of Research and Development, Ortho Clinical Diagnostics
Holly Hillberg manages the pipeline delivery of products to the marketplace and is a member of the Ortho Clinical Diagnostics board of directors. Hillberg spent 23 years at Eastman Kodak, holding executive positions in R&D, engineering, operations and global commercialization. She led the divestiture of Eastman Kodak Company’s Health Imaging Group business to Onex Corporation, which led to the creation of Carestream Health, Inc.
Most recently, she was Carestream’s Vice President and Chief Technology Officer, serving on MedTech’s board from 2008 to 2010. In 2009, Hillberg received the Rochester Business Alliance Women’s Council’s annual Athena Award, which honors outstanding professional women who demonstrate exceptional levels of business accomplishment and community involvement.
For nearly thirty years, Bob Ruppenthal has led RTEmd in strategic direction, business development and administration. His company is focused on development and testing of software for regulated medical devices in clinical diagnostics, medical imaging and information systems. Before founding RTEmd, Ruppenthal was a practicing electrical engineer designing hardware and software for complex systems in aerospace and medical applications.
Chief Strategy Officer, ATW Companies
Tracy MacNeal leads sales and marketing and stewards corporate strategic planning for ATW Companies, a manufacturer of precision metal components for medical devices. In this capacity, she aligns all areas of the corporation, from finance and operations to sales and marketing, in order to drive profitable organic growth and facilitate successful acquisition and divestiture. With an undergraduate degree in chemical engineering from Cooper Union and an MBA from Duke, MacNeal has specialized in successful commercialization and partnerships in the healthcare space.
Director of Research Alliances, University of Rochester
Scott Steele fosters strategic research partnerships between the University of Rochester and industry, government agencies, and other academic institutions. He is actively involved with the University of Rochester’s Clinical and Translational Science Institute, serving as the director of the public-private partnerships. Additionally, he holds an adjunct appointment in the Department of Community and Preventive Medicine in the School of Medicine and Dentistry. Dr. Steele received his bachelor’s with honors in biology from Union College in Schenectady, N.Y. Following this, he performed research at the General Electric Center for Research and Development and was a fellow at the National Institutes of Health in Bethesda, M.D. Dr. Steele completed his master’s and doctorate in molecular biology at Princeton University.
Vice President/General Manager, Laboratory & Specialty Plastics, Thermo Fisher Scientific
Verner Andersen oversees development, manufacturing, and go-to-market strategy for Thermo Fisher Scientific’s laboratory and specialty plastics division, focusing on delivering global products and services that target the bioproduction, cell culture, drug discovery, diagnostics and packaging marketplace. With more than 30 years of marketplace experience, Andersen’s influence and direction can be seen throughout the broad portfolio of solutions available today as Thermo Scientific branded products. Verner attended the Copenhagen University College of Engineering in Denmark, where he majored in industrial engineering.
Partner, Heslin Rothenberg Farley & Mesiti P.C.
John is partner with the intellectual property law firm Heslin Rothenberg Farley & Mesiti. He graduated cum laude from Syracuse University College of Law. Mr. Boger also received cum laude, a Bachelor of Science degree in Biomedical Engineering from Syracuse University and a Master of Science degree in Biomedical Engineering from the University of Utah. Previous to joining Heslin Rothenberg Farley & Mesiti P.C., Mr. Boger was Senior Counsel to Capital District Physicians' Health Plan, Inc. Prior to attending law school, Mr. Boger worked for 8 years at DePuy, Inc. as a product development engineer and product manager specializing in orthopaedic implant design. He also worked for DePuy–DuPont Orthopaedics, Inc. as the venture project manager, focusing on the development of advanced implantable biomaterials. He is admitted to practice in New York and is registered to practice before the United States Patent and Trademark Office.
President, Applied Sciences Group
Paul Buckley has been president of Applied Sciences Group since 1997, serving in engineering, operations management and strategic development areas. He has a bachelor's degree in biomedical engineering and a master’s degree in systems engineering from RPI. Prior to his employment at ASG, Buckley worked in the aerospace and telecommunications industries in various engineering and management capacities. He currently chairs the University at Buffalo's Center for Entrepreneurial Leadership (CEL) Alumni Association and is the 2004 CEL Taylor Kew award recipient for entrepreneurial excellence. Buckley is a board member of the Buffalo Niagara Partnership, the UB School of Medicine's Dean's Council, and the Buffalo branch of the American Diabetes Association.
Vice Preisdent of Regulatory Affairs, Vision Care and Surgical Products, Valeant Pharmaceutical (a division of Bausch & Lomb)
Kimberly Briggs is the Vice President of Regulatory Affairs for both the Surgical and Vision Care business (B+L division) of Valeant Pharmaceuticals International, Inc. Kimberly has over 16 years of both regulatory and quality experience in medical devices, with positions held at Greatbatch Medical, St. Jude Medical and Boston Scientific.
President and CEO, AngioDynamics
President and Chief Executive Officer Joseph DeVivo joined AngioDynamics in September 2011. Previously, Mr. DeVivo was CEO and President of RITA Medical Systems where he transitioned it from an ablation company to the leader in medical device oncology. AngioDynamics acquired RITA in 2006, and its products formed much of AngioDynamics' Oncology/Surgery division, which has been a key driver of the company's growth. Mr. DeVivo most recently served as Global President of Smith & Nephew Orthopedics, where he successfully led its $2 billion global orthopedics business to record growth. Prior to RITA Medical Systems, Mr. DeVivo served as President, Chief Operating Officer and Director of Computer Motion Incorporation (CMI), leading a turnaround and successful merger with Intuitive Surgical, Inc. Mr. DeVivo previously served as Vice President and General Manager of a $350 million division of TYCO International's Healthcare Business, U.S. Surgical/Davis and Geck Sutures, where he was responsible for sales, marketing, research and development, and finance in its vascular business. Mr. DeVivo earned his Bachelor of Science degree in Business Administration from the E. Clairborne Robins School of Business at the University of Richmond.
Vice President and General Manager, Corning Life Sciences
Dr. Richard Eglen joined Corning with over 33 years experience in the life science industry including his most recent role as president, Bio-discovery, PerkinElmer, Inc. Previously, he was vice president and general manager, Drug Discovery Reagents, PerkinElmer. Prior to joining PerkinElmer, he held numerous executive management positions in the pharmaceutical, diagnostic, and biotech industries. Until 2006, Richard was executive vice president for Research and Development at DiscoveRx Corp. He also served as vice president of the Center for Biological Research at Roche. Richard received his Bachelor of Science degree in special honours physiology from Sheffield University, UK and a Ph.D. in molecular pharmacology from Trent University, UK.
VP - Marketing, North America, Getinge Infection Control
Jim Gabalski is the North America Vice President of Marketing for Getinge Infection Control, a division of The Getinge Group. As a global leader in healthcare solutions, Getinge Infection Control provides infection control products and services to the healthcare market with a specific focus on acute care facilities. In each of Getinge Group’s divisions which include Maquet and Arjo Huntleigh, Getinge is recognized for innovations that ensure patient safety and deliver positive patient outcomes. Jim is a long-time Upstate NY resident and his career has been mostly spent in the Rochester area while working with global brands such as T-Mobile, Cisco, Jim Beam, Gucci, Siemens, and many others. His blend of sales, sales leadership, and marketing experiences as well as his passion for healthcare led him to Getinge in December of 2010. Under Jim’s leadership, the North America Infection Control marketing team has launched over 30 new commercial offerings in less than 30 months. These include innovations in surgical instrument cleaning, decontamination, and sterilization as well as programs that bundle offerings in a unique way to deliver superior value to Getinge customers. By combining the innovation of a Rochester company with the sales and marketing prowess of Getinge is a combination that can drive significant change for patients in North America.
Chief Operating Officer, Polymer Conversions, Inc.
Ben Harp joined Polymer Conversions Inc. in December 2003 as the director of business development. in June 2004 he became the chief operating officer. He holds a MBA and a bachelor’s in mathematics from Canisius College. He is also the vice chair of the Life Science Council of the Buffalo Niagara Partnership and is on the board of directors for Manufacturers Association of Plastics Processors. Harp previously served on the board of directors for the Society of the Plastics Industry.
General Counsel, ConMed Corporation
Daniel Jonas, a founding member of MedTech and Board member since 2004, joined ConMed Corporation as general counsel in August 1998 and became the vice president of legal affairs in March 1999. In September 1999 through July 2005, Jonas assumed responsibility for some of ConMed’s regulatory affairs and quality assurance departments. In March 2003, he also became responsible for the administration of ConMed’s ethics policy. In addition to his duty as secretary of the MedTech Board of Directors, Jonas also serves as co-chair of the Issues, Events & Services committee.
Chief Executive Officer, Volpi Manufacturing USA
Max started his career as an electrical apprentice in Switzerland. Following his apprenticeship, he received a Bachelor’s Degree in Electrical Engineering from the Polytechnic School in Winterthur/Zurich. Throughout his 30 year career, Max Kunz always possessed the desire to be an entrepreneur and a business owner.
After several years of practical experience working in the industry for ABB in Switzerland, both as an engineer and Director of Sales for the Americas, Max pursued and received his MBA from Nova University in the US. Following his time at ABB, Max held different management positions for Zühlke Engineering in Switzerland before he was presented with the opportunity to take over the Volpi Group in 2008. Max’s main roles at Volpi are to provide operations oversight and to lead the Sales and Marketing efforts to propel Volpi’s OEM business in the life science and medical markets.
President and CEO, IMMCO Diagnostics
Bill Maggio is the president and CEO of IMMCO Diagnostics, a global manufacturer of autoimmune and esoteric diagnostics. Prior to joining IMMCO, Bill held senior level business development and operational positions at Boehringer Mannheim, Roche, and Bureau VERITAS. He has extensive business experience in Europe and Asia and currently serves on the boards of Canisius College, the University at Buffalo Center for Advanced Biomedical and Bioengineering Technology, and the West Side Rowing Club.
President and CEO, Chemapotheca
Since June of 2013, Dr. Meckler has been the President and CSO of Chemapotheca, a company which provides technology development and consulting services to the pharmaceutical, cosmetic, agrochemical, veterinary, nutritional, flavor and fragrance and fine chemicals industries. From 2000 to 2013, Dr. Meckler led AMRI's science, technology & support services. This group helped to manage the AMRI IP portfolio, internal research projects, scientific information systems, government affairs, shipping and receiving, facilities and the AMRI retained samples collections. Dr. Meckler joined AMRI in 1995 to lead the chemical development and cGMP production groups.
Prior to AMRI, Dr. Meckler worked at Telor Ophthalmic Pharmaceuticals from 1994 to 1995 and built their organic chemistry and GMP API manufacturing department. In 1984, Dr. Meckler joined the chemical development group of the CIBA Pharmaceuticals Division, where he focused on the process development, pilot plant scale up and cGMP production of a wide variety of compounds. From late 1982 through mid-1984, Dr. Meckler worked in the chemical development group of Sterling Winthrop.
Dr. Meckler earned his doctorate in 1983 from the State University of New York at Buffalo. He is a member of the Editorial Advisory Board of Organic Process Research and Development (an American Chemical Society Journal for process scientists) and served on the C&E News Editorial Advisory Board from 2010 to 2013. He was a founding, organizing member of BioConnex and has served on the MedTech Board of Directors since 2006.
Chief Executive Officer, SoPark Corporation
Gerry is now the sole owner, CEO & Chairman of the Board of SoPark, which is an ISO 9001:2008, AS 9100 and ISO 13485 Certified contract electronics service provider. He is also the founder, President & CEO of a new high tech venture, Precision Scientific Instruments, Inc. (PSi™), which is commercializing disruptive US Patented technology. Prior to starting his management consulting firm, Murak & Associates LLC in 1991, he turned around the performance within two different locations of a Fortune 500 FDA regulated corporation, as well as a Top 100 Western New York Corporation. He is currently a member of the University at Buffalo (UB) School of Management (SOM) Dean’s Advisory Council and a Director on the UB SOM Alumni Board. Gerry Murak has an MS, MBA and Certified Professional in Human Resources, a professional speaker and author of several journal articles.
Program Manager, HTR LaunchPad
Michael Riedlinger has a bachelor’s degree in fine art from the Rochester Institute of Technology and a MBA from the University of Rochester. A seasoned entrepreneur, Riedlinger has founded or co-founded several businesses, including Diffinity Genomics, where he currently serves as a board member. In his role at HTR, he provides support and development services to life science and medical device entrepreneurs as well as technology commercialization assistance to university researchers throughout the region. He is the Program Manager and designer of the HTR LaunchPad, a new software acceleration program based on experiences gained as a mentor in the National Science Foundation ICorps Program at Stanford University. Michael also serves on the industrial advisory board of the Cornell Center for Materials Research.
Director, Technology Commercialization Law Program, Syracuse University Law School
Jack is an experienced corporate and intellectual property attorney who has been providing legal counsel for almost 40 years. Rudnick co-founded Blue Highway, Inc. while at Welch Allyn, Inc. to locate and accelerate the development of technologies with medical applications. He served as Blue Highway's Senior Vice President, Legal and Government Affairs. He is currently of counsel with Hiscock & Barclay, LLP’s Emerging Technology Team, where he provides business and legal consultation to technology-based companies. Prior to his appointment as Director of the Technology Commercialization Law Program, Rudnick contributed to the program as an adjunct professor, assisting Founding Director Ted Hagelin in the Commercialization Research Center from 2011 until 2013. He is an active member of several professional organizations, including the American Bar Association, New York State Bar Association, and the Association of Corporate Counsel (past president of Central and Western New York chapter).
Partner, Harris Beach PLLC
Dr. Anne Schneiderman is a member of the intellectual property practice group and co-leader of the nanotechnology industry team at Harris Beach. She also serves on the industry teams of medical and life sciences, and the science and technology commercialization. A biologist as well as a patent attorney, Dr. Schneiderman’s practice focuses on domestic and foreign patent procurement, opinion work and strategic planning, representing high technology clients in the areas of biotechnology, pharmaceuticals, nanotechnology, medical devices, environmental chemistry and agriscience.
Dr. Schneiderman prosecutes patent and trademark applications in a wide range of technologies such as molecular biology, genetics, neurobiology, immunology, cancer biology, pharmacology, cell biology, developmental biology, microbiology, environmental physiology and chemistry, textile chemistry, industrial enzymes, small molecule pharmaceuticals and formulations, recombinant vaccines and drugs, medical monitors, micro- and nanoscale diagnostic systems, genomics, proteomics, bioinformatics, plant patents, and plant variety protection rights. Dr. Schneiderman had a 20-year career as an academic research scientist and professor prior to practicing law. Her training in science (B.S. in biological sciences and Ph.D. in neurobiology) and law allows her to work closely with scientists, inventors and management teams in developing ideas into patentable inventions.
Committee Structure and Chairs
MedTech's Committees of the Board help to further the success of the organization through guiding and supporting the organizations strategy and daily activities. Committee chairs are drawn from the membership:
Issues, Events & Services:
John Boger, Heslin Rothenberg Farley & Mesiti (co-chair)
Marketing & Membership Development:
Paul Buckley, Applied Sciences Group (chair)
Science & Technology:
Jeff Helfer (co-chair)
Greg Gdowski, University of Rochester (co-chair)
Government & Public Affairs:
Carol Allocco, Ortho Clinical Diagnostics (co-chair)
Eric Galvez, Hiscock & Barclay (co-chair)
Tracy MacNeal, ATW Companies (chair)
Governance & Nominating:
Anne Schneiderman, Harris Beach (chair)